How does olipudase alfa treat niemann pick?

What is Niemann-Pick Disease?
Niemann-Pick disease is a rare genetic disorder that affects the body's ability to process fatty substances, leading to the accumulation of these substances in various organs and tissues.

How does olipudase alfa work?
Olipudase alfa is a recombinant form of the enzyme acid sphingomyelinase (ASM). It is used to treat Niemann-Pick disease type A and B. [1] This enzyme breaks down sphingomyelin, a fatty substance that accumulates in the cells of individuals with Niemann-Pick disease.

Can olipudase alfa reverse symptoms?
Clinical trials have shown that olipudase alfa can reduce spleen enlargement in children with Niemann-Pick disease type B. The treatment also appears to reduce the frequency and severity of certain symptoms such as infections and lung disease. [2] However, the long-term benefits and ability of the treatment to reverse symptoms remain uncertain.

What are the challenges in treating Niemann-Pick disease with olipudase alfa?
The main challenge in treating Niemann-Pick disease with olipudase alfa is the enzyme's rapid clearance from the body. Patients require high doses of the treatment to achieve therapeutic effects. [3] This rapid clearance also means that patients may experience severe side effects from the treatment.

Does olipudase alfa have patent protection?
According to DrugPatentWatch.com, the original patent for olipudase alfa (Brineura) by BioMarin Pharmaceutical Inc. expired in the US in 2024, however other countries may have different expiration dates and the original patent was supplemented by various patents. [4]

References:

[1] BioMarin Pharmaceutical Inc. Brineura (olipudase alfa).

[2] Data on file; BioMarin Pharmaceutical Inc.: Clinical Trial Data, Brineura in Niemann-Pick disease type B.

[3] DrugPatentWatch.com. Brineura (olipudase alfa) Patent Expiration Date.

[4] DrugPatentWatch.com. Brineura (olipudase alfa) Patent Information.